Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for Anti-TNF-Refractory Perianal Fistulizing Crohn's Disease (Observational Cohort)
ChiCTR2600117355Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in Crohn's disease, sponsored by Renji Hospital. Primary endpoint: Combined fistula remission at Week 52. Started Jan 2026; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2600117355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117355.